January 18, 2019 / 9:47 PM / 3 months ago

AbbVie's cancer drug fails to meet main goal in late-stage study

Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

The treatment, ibrutinib, failed to show statistically significant improvement, compared to placebo, in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below